,

Investor Briefing with James McDonnell – 21 October 2026

October 21, 2026

Prescient Therapeutics: Investor Briefing with CEO James McDonnell

CEO, James McDonnell, held an investor briefing with Reach Markets, off the back of their recent 4C announcement.

In this session, James discussed:

  • The Dose Optimisation Committee meeting in December, a key catalyst for a potential accelerated commercial pathway for PTX-100.
  • The types of deals being done in the sector and what they mean for Prescient, including comments around active discussions with large and mid-tier pharmaceutical companies. 
  • Key upcoming milestones for PTX-100, one of the most advanced therapies on the ASX1 and well funded for the next stage of development.

PTX-100 is at an advanced stage in clinical trials and at the point where large pharmaceutical companies may begin to take a serious interest in de-risked assets like this. We have an opportunity to potentially become one of Australia’s biotech success stories.

Recorded on 21st October 2026 at 11am (AEDT)

Join the next Prescient Therapeutics webcast

Register to stay up to date with Prescient Therapeutics

 1 Based on public data

Featured Speaker

James McDonnell

CEO

James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.

Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.

James is a registered pharmacist and a member of the Royal College of Pharmacy. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.

Related Post

This investor centre was built by Reach Markets

©2026 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.